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Background
Tamoxifen and raloxifene have limited patient acceptance for primary prevention of 
breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and 
cause fewer side effects than tamoxifen in patients with early-stage breast cancer.
Methods
In a randomized, placebo-controlled, double-blind trial of exemestane designed to 
detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal 
women 35 years of age or older had at least one of the following risk factors: 60 years 
of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive 
breast cancer developing within 5 years); prior atypical ductal or lobular hyperpla-
sia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic 
effects and health-related and menopause-specific qualities of life were measured.
Results
A total of 4560 women for whom the median age was 62.5 years and the median 
Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. 
At a median follow-up of 35 months, 11 invasive breast cancers were detected in 
those given exemestane and in 32 of those given placebo, with a 65% relative reduc-
tion in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ra-
tio, 0.35; 95% confidence interval [CI], 0.18 to 0.70; P = 0.002). The annual incidence 
of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on 
exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; 
P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the 
placebo group (P = 0.003), with no significant differences between the two groups 
in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-
related deaths. Minimal quality-of-life differences were observed.
Conclusions
Exemestane significantly reduced invasive breast cancers in postmenopausal wom-
en who were at moderately increased risk for breast cancer. During a median fol-
low-up period of 3 years, exemestane was associated with no serious toxic effects 
and only minimal changes in health-related quality of life. (Funded by Pfizer and 
others; NCIC CTG MAP.3 ClinicalTrials.gov number, NCT00083174.)
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Estrogens contribute to normal breast development but can also promote breast cancer in preclinical models and in 
women with high circulating plasma estrogen 
levels.1-4 To date, chemoprevention of breast can-
cer has focused on the selective estrogen-receptor 
modulators (SERMs) tamoxifen and raloxifene, 
which exert antiestrogenic effects on the breast, as 
well as agonist or antagonist effects on other or-
gans. In the National Surgical Adjuvant Breast and 
Bowel Project P-1 trial, tamoxifen significantly re-
duced the number of invasive breast cancers, by 
49% (P<0.001) as compared with placebo.5 A meta-
analysis of trials comparing tamoxifen with place-
bo showed that tamoxifen reduced the incidence of 
breast cancer by 38% with no effect on mortality.6 
On the basis of these collective data on tamoxifen, 
the estimated number needed to treat to prevent 
one breast cancer after 5 years is about 95 and is 
reduced to 56 after 10 years.7 Similar risk reduc-
tions occur with raloxifene.8-10 Tamoxifen increases 
the risks of endometrial cancers and venous throm-
boembolism; raloxifene does not increase the risk 
of endometrial cancers but does cause similar toxic 
effects.
The acceptance of tamoxifen or raloxifene for 
reducing the risk of breast cancer has been poor, 
in part because they are both associated with 
rare but serious toxic effects.11-13 Of the approxi-
mately 2 million U.S. women who could poten-
tially benefit from treatment with tamoxifen, only 
4% of those at increased risk for breast cancer 
and only 0.08% of all U.S. women 40 to 79 years 
of age have accepted the use of this drug for 
chemoprevention.13-15 A 2002 expert assessment 
concluded that tamoxifen lacks overall health 
benefits and recommended that future trials be 
conducted with placebo controls.16 Novel, less 
toxic interventions are needed that will reduce 
the threshold of risk yet provide a net benefit.17
Aromatase inhibitors profoundly suppress es-
trogen levels in postmenopausal women and in-
hibit the development of breast cancer in labora-
tory models.18-21 In early trials of breast cancer 
therapy, both nonsteroidal and steroidal aromatase 
inhibitors reduced contralateral primary breast 
cancers more than did tamoxifen; after 5 years of 
tamoxifen therapy, letrozole resulted in a further 
reduction of 46%, as compared with placebo.22-27 
Preclinical models and clinical studies suggest that 
because of exemestane’s antiestrogenic effects, 
such as those on bone resorption due to this drug’s 
mild androgenic activity, it is a good candidate 
for study in a breast-cancer prevention trial.28-30
Me thods
Study Design
The NCIC Clinical Trials Group Mammary Preven-
tion.3 trial (NCIC CTG MAP.3) is an international, 
randomized, double-blind, placebo-controlled tri-
al conducted in Canada, the United States, Spain, 
and France. The trial was approved by the health 
regulatory authorities and institutional review 
boards at the participating centers, and enrollment 
began in September 2004. After stratification ac-
cording to current use of low-dose aspirin (≤100 mg 
per day) (yes or no) and Gail risk score (for calcu-
lation of this score, see www.cancer.gov/bcrisktool 
and the Supplementary Appendix, available with 
the full text of this article at NEJM.org) (≤2.0% or 
>2.0%), subjects were randomly assigned to one of 
three treatment groups with the use of a dynamic 
minimization algorithm: 25 mg of exemestane plus 
placebo, 25 mg of exemestane plus celecoxib, or pla-
cebo plus placebo pills, administered daily after a 
morning meal.31,32 After 31 patients were enrolled, 
10 patients discontinued treatment with celecoxib 
because of concern for cardiovascular safety.33 Be-
fore enrollment and during the study, written in-
formed consent and reconsent in all the participat-
ing countries included counseling about the risks 
and benefits of treatment with tamoxifen and ral-
oxifene. The trial was event-driven, with a planned 
maximum duration of therapy of 5 years or until a 
breast event, a neoplastic disease, or a cardiovas-
cular event was diagnosed or unacceptable toxicity 
developed.
Participants
Women 35 years of age or older were eligible if they 
were postmenopausal (older than 50 years of age 
with no spontaneous menses for at least 12 months; 
or 50 years of age or younger either with no spon-
taneous menses [amenorrheic] within 12 months 
of randomization [e.g., spontaneous or second-
ary to hysterectomy] and a follicle-stimulating 
hormone level within the postmenopausal range 
or with prior bilateral oopho rectomy). In addition, 
women had at least one of the following risk fac-
tors: age 60 years or older; Gail risk score greater 
than 1.66%; prior atypical ductal or lobular hyper-
plasia or lobular carcinoma in situ on breast biopsy 
or prior ductal carcinoma in situ treated with mas-
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tectomy. Prior menopausal hormone therapies 
(estrogen with or without progestin), luteinizing 
hormone–releasing hormone analogues, prolactin 
inhibitors, antiandrogens, or selective estrogen-
receptor modulators were allowable, but not with-
in 3 months of randomization. Women were in-
eligible if they were premenopausal, had prior 
invasive breast cancer or prior ductal carcinoma in 
situ treated with lumpectomy, were known carri-
ers of the BRCA1 or BRCA2 gene, had a history of 
other malignancies (except nonmelanoma skin can-
cer, treated in situ cancer of the cervix, or other 
solid tumors treated with no evidence of disease 
for 5 years), had uncontrolled hypothyroidism or 
hyperthyroidism, or had chronic liver disease.
End Points and Assessment
The primary outcome was incidence of invasive 
breast cancer. Secondary end points included a 
combined incidence of invasive and noninvasive 
(ductal carcinoma in situ) breast cancer; inci-
dence of receptor-negative invasive breast can-
cer; incidence of combined atypical ductal hyper-
plasia, atypical lobular hyperplasia, and lobular 
carcinoma in situ; number of clinical breast bi-
opsies; clinical fractures; adverse cardiovascu-
lar events, including myocardial infarction or 
coronary heart disease that resulted in death; 
overall incidence of other cancers; the side-effect 
profile and safety; and health-related and meno-
pause-specific qualities of life (assessed by means 
of the Medical Outcomes Study 36-Item Short-
Form Health Survey [SF-36] and the Menopause-
Specific Quality of Life [MENQOL] questionnaire, 
respectively34-36).
At baseline, each patient’s history of prior dis-
eases and treatment, family history of cancer, 
and reproductive history were obtained. Physical 
examination was performed, including height, 
weight, blood pressure, pulse, and clinical breast 
examination to confirm no suspicious breast ab-
normalities. Other requirements included complete 
blood count, liver-function tests, renal-function 
tests, and normal results on bilateral mammogra-
phy and bone-mineral-density measurements with-
in the past year. Symptoms at baseline were graded 
according to the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events 
(CTCAE), version 3.0.37 Quality of life (QOL) was 
measured within 1 week before randomization. 
Clinical assessments occurred at 6 and 12 months 
after randomization and yearly thereafter and in-
cluded physical examination with clinical breast 
examinations, recording of concomitant medica-
tions, symptoms and adverse events, and QOL as-
sessments. Women discontinuing the study drug 
continued to undergo clinical assessments and 
follow-up for clinical outcomes and adverse events.
Mammography was required within 12 months 
before randomization and every 12 months from 
the time of the initial mammogram during and 
after the treatment. Breast cancers could be de-
tected on clinical breast examination during the 
clinic visits or on annual mammography. All mam-
mograms and radiographic reports of fractures 
were reviewed centrally, and all evidence of dis-
ease on breast-biopsy specimens was reviewed by 
an adjudication committee. Study accrual and 
safety data were reviewed every 6 months by an 
independent data and safety monitoring commit-
tee. The original protocol and subsequent amend-
ments are available at NEJM.org.
Statistical Analysis
The planned final analyses presented here in-
clude invasive breast cancer incidence and other 
secondary breast cancer end points, estimated on 
the basis of time from randomization to when an 
end point was reached. The sample-size estimate 
was based on an assumption of a rate of invasive 
breast cancer of 0.60% per year in the group giv-
en placebo, as compared with 0.21% in those 
treated with exemestane, with a relative reduc-
tion of 65% with exemestane. To detect this with 
a two-sided 5% level and 90% power, a total of 
38 cases of invasive breast cancer were required, 
projected to occur when 4560 women were ran-
domly assigned to treatment groups in a 3-year pe-
riod and then followed for an additional 1.2 years. 
No interim analyses were planned. Accrual was 
completed on March 23, 2010; the protocol target-
event rate was met on November 5, 2010. All data 
queries were resolved, and the database was locked 
on March 1, 2011.
Comparisons of time-to-event primary and 
secondary end points were based on the stratified 
log-rank test, adjusting for the two stratification 
factors at randomization. Cox proportional-hazards 
models were used to derive hazard ratios and as-
sociated 95% confidence intervals. Fisher’s exact 
test was used to compare adverse events between 
the treatment and placebo groups. Mean change 
scores from baseline to each assessment were 
calculated for all SF-36 and MENQOL subscales 
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and summaries. Changes measuring 5 to 10% of 
the scale breadth or 0.5 SD were considered to be 
potentially clinically meaningful.38-40 Scores mea-
suring changes in QOL were considered worsened 
if they decreased by 5 or more points (out of a 
total of 100) from baseline on the SF-36 and if they 
increased by 0.5 or more points (out of a total of 
8) on the MENQOL. A chi-square test was used to 
compare the differences in proportions of patients 
found to have potentially clinically meaningful 
changes in QOL.
The study drug, exemestane, and funding sup-
port were provided by Pfizer, but this sponsor 
had no role in the design of the study or in the 
accrual, management, or analysis of the data. The 
decision to publish and the drafting of the man-
uscript were undertaken entirely by the first au-
thor, coauthors, and staff at the NCIC CTG cen-
tral office, who vouch for the fidelity of the study 
to the protocol and for the accuracy and com-
pleteness of the data.
R esult s
Between February 11, 2004, and March 23, 2010, 
4560 women were randomly assigned to either ex-
emestane (2285 patients) or placebo (2275 pa-
tients). After randomization, 15 women (6 taking 
exemestane and 9 taking placebo) were considered 
to be ineligible to continue with the study but are 
included in the primary intention-to-treat analysis 
as randomly assigned. The exemestane and place-
bo groups were well balanced for race, body-mass 
index, and breast cancer risk factors (Table 1, and 
Table 1 in the Supplementary Appendix). Major risk 
factors among the women who were enrolled in-
cluded age of at least 60 years (49%); 5-year risk of 
breast cancer developing (Gail risk score >1.66%) 
(40%), and prior atypical ductal hyperplasia, atyp-
ical lobular hyperplasia, lobular carcinoma in situ, 
or prior ductal carcinoma in situ treated with mas-
tectomy (11%). Prior menopausal hormone therapy 
use was recorded in 1310 women in the exemestane 
group (57.3%; range from 1 to 588 months) and 
1327 women in the placebo group (58.3%; range 
from 1 to 360 months). Pretreatment bone mineral 
density and prior history of clinical fractures, car-
diovascular risk factors, and the concomitant use of 
bisphosphonates, lipid-lowering drugs, and cardio-
vascular drugs were similar in the two study groups.
On November 5, 2010, at the time of the 
clinical data cutoff, 735 women (32.8%) assigned 
Table 1. Baseline Characteristics of Patients Randomly Assigned






White race — no. of patients (%)† 2138 (93.6) 2123 (93.3)
Age
Median — yr 62.5 62.4
Range — yr 38.5–88.2 37.1–89.9




Breast cancer risk factors — no. of  
patients (%)
Gail score indicating 5-year risk >1.66%§ 929 (40.7) 905 (39.8)
Age ≥60 yr 1114 (48.8) 1126 (49.5)
Prior ADH, ALH, or LCIS on breast 
biopsy
185 (8.1) 188 (8.3)
Prior DCIS treated with mastectomy 56 (2.5) 56 (2.5)
Gail 5-yr risk score§
No. of patients assessed 2171 2163
Median score — % 2.3 2.3
Range 0.6–21.0 0.6–15.1
Score >2.0 — no. of patients (%) 1321 (57.8) 1300 (57.1)
Prior therapy — no. of patients (%)
Hormone-replacement therapy 1310 (57.3) 1327 (58.3)
Bisphosphonate therapy 427 (18.7) 414 (18.2)
Lipid-lowering drugs 738 (32.3) 696 (30.6)
Cardiovascular drugs 955 (41.8) 973 (42.8)
Selective estrogen-receptor modulators 104 (4.6) 116 (5.1)
Medical conditions — no. of patients (%)
Prior clinical skeletal fracture 409 (17.9) 400 (17.6)
Current osteoporosis 303 (13.3) 293 (12.9)
Prior cardiovascular event 267 (11.7) 255 (11.2)
Bone mineral density
In total hip
No. of patients assessed 2136 2136
Mean value — g/cm2 0.92±0.16 0.92±0.14
In L1–L4 posteroanterior spine
No. of patients assessed 1990 2010
Mean value — g/cm2 1.06±0.39 1.06±0.39
* Plus–minus values are means ±SD. Women may have received more than one 
prior therapy and may have had more than one medical problem. ADH denotes 
atypical ductal hyperplasia, ALH atypical lobular hyperplasia, DCIS ductal carci-
noma in situ, and LCIS lobular carcinoma in situ.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
§ The Gail score calculates breast cancer risk based on known clinical risk factors 
(see www.cancer.gov/bcrisktool and the Supplementary Appendix at NEJM.org).
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to exemestane and 646 women (28.7%) assigned to 
placebo were no longer taking the study medica-
tion. About 5% in each group had discontinued 
the protocol treatment because of treatment com-
pletion. The major reasons for early discontinu-
ation of the protocol treatments were toxic effects 
(15.4% in the exemestane groups vs. 10.8% in the 
placebo group, P<0.001) and patient refusal 
(6.9% vs. 6.0%, P = 0.22). The median time from 
randomization to off-protocol treatment was 10.2 
months (range, 0.1 to 61.5) for exemestane and 
14.2 months (range, 0.1 to 62.9) for placebo. Ap-
proximately 85% of women were compliant and 
15% were noncompliant with the protocol guide-
lines for the study treatments. Scheduled annual 
mammography was performed equally in the two 
groups, with 7.2% and 7.7% of women having 
missed at least one scheduled mammography ap-
pointment in the exemestane and placebo groups, 
respectively.
At a median of 35 months of follow-up (range, 
0 to 63.4), 43 invasive breast cancers were diag-
nosed: 11 in the exemestane groups and 32 in 
the placebo group (annual incidence, 0.19% with 
exemestane vs. 0.55% with placebo; hazard ratio, 
0.35 with exemestane; 95% confidence interval 
[CI], 0.18 to 0.70) (Table 2). Figure 1 shows the 
cumulative incidence of invasive breast cancer in 



















All cases 11 0.19 32 0.55 0.35 (0.18–0.70) 0.002
ER-positive 7 0.12 27 0.46 0.27 (0.12–0.60) <0.001
ER-negative 4 0.07 5 0.09 0.80 (0.21–2.98) 0.74
PR-positive 5 0.09 20 0.34 0.26 (0.10–0.69) 0.004
PR-negative 6 0.10 12 0.20 0.50 (0.19–1.33) 0.16
HER2/neu-positive 0 0.00 6 0.10 NA NA
HER2/neu-negative 10 0.17 26 0.44 0.40 (0.19–0.82) 0.01
HER2/neu unknown 1 NA 0 NA NA NA
T stage 1 8 0.14 28 0.48 0.29 (0.13–0.65) 0.001
T stages 2 to 4 3 0.05 3 0.05 0.98 (0.20–4.86) 0.98
T stage X 0 NA 1 NA NA NA
Node-positive 3 0.05 9 0.15 0.33 (0.09–1.71) 0.08
Node-negative 7 0.12 22 0.38 0.33 (0.14–0.78) 0.008
Node unknown 1 NA 1 NA NA NA
M stage 0 11 0.19 30 0.51 0.38 (0.19–0.75) 0.004
M stage X1 0 NA 2 NA NA NA
DCIS§ 9 0.16 14 0.24 0.65 (0.28–1.51) 0.31
Invasive breast cancer 
and DCIS§
20 0.35 44 0.77 0.47 (0.27–0.79) 0.004
ADH, ALH, and LCIS 4 0.07 11 0.20 0.36 (0.11–1.12) 0.08
* ADH denotes atypical ductal hyperplasia, ALH atypical lobular hyperplasia, CI confidence interval, DCIS ductal carcinoma 
in situ, ER estrogen receptor, HER2 human epidermal growth factor receptor type 2, LCIS lobular carcinoma in situ, NA 
not available (i.e., not calculated because of small number of events), and PR progesterone receptor.
† The hazard ratio is for the comparison of exemestane with placebo.
‡ P values were obtained with the use of a stratified log-rank test.
§ Women with prior DCIS at baseline were excluded.
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these two groups. There were 37 ductal (10 in the 
exemestane groups and 27 in the placebo group) 
and 6 lobular (1 in the exemestane groups and 5 in 
the placebo group) cancers. The majority of can-
cers in each group were estrogen-receptor–positive, 
HER2/neu–negative, and node-negative (Table 2). 
Exemestane appeared to be superior to placebo in 
all prespecified subgroups defined by concurrent 
use of low-dose aspirin, Gail risk score, age, body-
mass index, prior atypical ductal hyperplasia, 
atypical lobular hyperplasia, or lobular carcinoma 
in situ and prior ductal carcinoma in situ treated 
with mastectomy (Fig. 2). Exemestane also ap-
peared to be superior in unplanned subgroups: 
invasive breast cancers according to prior use of 
menopausal hormone therapy (hazard ratio, 0.30 
for prior users; 95% CI, 0.11 to 0.81; hazard ratio, 
0.41 for prior nonusers; 95% CI, 0.16 to 1.05) and 
continent of residence (hazard ratio, 0.34 for North 
America; 95% CI, 0.16 to 0.71; hazard ratio, 0.39 for 
Europe; 95% CI, 0.07 to 1.99). The annual incidence 
of invasive breast cancer plus ductal carcinoma 
in situ (20 in the exemestane group and 44 in the 
placebo group) was 0.35% and 0.77% in the exe-
mestane and placebo groups, respectively (hazard 
ratio, 0.47; 95% CI, 0.27 to 0.79). Combined lobular 
carcinoma in situ, atypical ductal hyperplasia, and 
atypical lobular hyperplasia occurred in 4 women 
(0.2%) in the exemestane group and 11 (0.5%) in 
the placebo group (hazard ratio, 0.36; 95% CI, 0.11 
to 1.12). The number needed to treat to prevent 
one case of invasive breast cancer with exemestane 
therapy was 94 in 3 years and 26 in 5 years, but 
few women completed 5 years of therapy.
Table 3 (and Table 2 in the Supplementary Ap-
pendix) shows adverse events that occurred in 
5% or more of women, with a difference between 
groups of 1% or more and prespecified secondary 
end points of toxicity. Symptoms and adverse 
events (all grades) occurred in 88% of women in 
the exemestane group versus 85% in the placebo 
group (P = 0.003). Arthritis (P = 0.01) and hot flashes 
(P<0.001) were more common in the exemestane 
group, but differences between the groups in the 
frequency of those with grade 2 or higher symp-
toms were modest (arthritis, 6.5% vs. 4.0%; hot 
flashes, 18.3% vs. 11.9%). Table 3 (and Table 2 in 
the Supplementary Appendix) shows no significant 
differences between the two groups in prespecified 
secondary end points, including new diagnoses 
of osteoporosis or cardiovascular events. Clinical 
fracture rates were also similar in the two groups, 
and the proportion of women in each group who 
were prescribed bisphosphonate therapy during 
the trial was also similar (24.5% for exemestane 



















































Hazard ratio, 0.35 (95% CI, 0.18–0.70)
P=0.002 by stratified log-rank test





Figure 1. Cumulative Incidence of Invasive Breast Cancer.
CI denotes confidence interval.
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difference in the number of cancers other than 
breast cancer (50 [2.2%] vs. 44 [2.0%]) or time to 
detection of these cancers (1.8 yr vs. 1.6 yr). No 
significant differences were detected between the 
two groups with respect to hypercholesterolemia, 
hypertriglyceridemia, abnormal liver-function 
tests, acne, alopecia, rash, weight gain, or hair loss 
(data not shown). Table 3 in the Supplementary 
Appendix shows health-related and menopause-
specific QOL results. Compliance in completing 
the QOL questionnaire at each follow-up visit 
was 92.9 to 97.4% for the exemestane group and 
94.3 to 97.5% for the placebo group. No between-
group differences in overall health-related QOL 
responses were found when distributions of wors-
ened, stable, and improved scores on the SF-36 
(Physical and Mental Component Scores) were com-
pared despite worsened menopause-specific QOL 
among those taking exemestane (7% more over-
all). There were 38 deaths during the study (19 in 
each group). Causes of death in the exemestane 
and placebo groups, respectively, were breast can-
cer, 1 and 0; other malignancies, 10 and 12; car-
diovascular events, 5 and 4; and other causes, 3 
and 3. None were adjudicated as treatment-related.
Discussion
In this randomized, placebo-controlled trial in 
healthy postmenopausal women, exemestane re-
duced the relative incidence of invasive breast can-
cers by 65%, from 0.55% to 0.19%. Exemestane 
also reduced the risk of known breast-cancer pre-
cursor lesions — ductal carcinoma in situ, lobu-
lar carcinoma in situ, atypical ductal hyperplasia, 
and atypical lobular hyperplasia — suggesting 
possible further reductions in invasive cancers 
during long-term follow-up. Most tumors in these 
study patients were estrogen-receptor–positive. 
HER2-positive tumors, which have a poor prog-
nosis, were also reduced with exemestane. Future 
studies to corroborate this finding would be im-
portant.
Menopausal symptoms such as hot flashes, 
fatigue, sweating, insomnia, and arthralgia were 
frequent among all the women in the study but 
were predictably somewhat more common in 
those taking exemestane. Also of potential clini-
cal importance, more women in the exemestane 
group self-reported that menopause-related vaso-
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Figure 2. Hazard Ratios for the Development of Invasive Breast Cancer, According to Planned Subgroup Analysis.
The subgroup of women with prior ductal carcinoma in situ is not shown because of insufficient events in this 
group. ADH denotes atypical ductal hyperplasia, ALH atypical lobular hyperplasia, CI confidence interval, and LCIS 
lobular carcinoma in situ.
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ever, these symptoms did not appear to affect 
self-reports of overall health-related QOL among 
those taking exemestane because summary mea-
sures of physical and mental components of the 
SF-36 did not differ between the two study groups. 
(Full QOL results are not reported here.) Unlike 
the rare endometrial cancers and thromboemboli 
associated with tamoxifen, particularly in post-








Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 1 Grade 2 Grade 3 Grade 4 Total
no. no. (%) no. no. (%)
Any 464 931 536 32 1963 (88) 557 877 437 30 1901 (85) 0.003
Cardiac: hypertension 119 109 112 1 341 (15) 124 118 109 3 354 (16) 0.65
Endocrine
Hot flashes 489 344 67 900 (40) 450 225 43 718 (32) <0.001
Fatigue 342 150 31 2 525 (23) 305 135 25 465 (21) 0.03
Sweating 284 201 1 486 (22) 263 169 1 433 (19) 0.046
Insomnia 117 98 15 230 (10) 127 55 7 189 (8) 0.04
Constitutional and 
 gastrointestinal
Diarrhea 77 32 9 118 (5) 58 16 1 75 (3) 0.002
Heartburn 223 92 17 332 (15) 200 79 10 289 (13) 0.06
Nausea 137 15 3 155 (7) 102 18 2 122 (5) 0.04
Musculoskeletal: arthritis 102 113 30 2 247 (11) 96 83 17 196 (9) 0.01
Neurologic
Dizziness 145 35 9 189 (8) 152 48 9 209 (9) 0.32
Mood alteration or 
depression
123 90 19 4 236 (11) 128 98 8 1 235 (10) 0.96
Pain
Back 106 77 21 2 306 (9) 119 80 23 222 (10) 0.45
Extremity 67 68 17 1 153 (7) 60 54 8 122 (5) 0.054
Joint 294 293 75 3 665 (30) 308 264 33 1 606 (27) 0.04
Muscle 69 62 16 147 (7) 111 67 14 192 (9) 0.01
Upper respiratory: cough 196 28 10 234 (10) 224 31 11 266 (12) 0.14
Sexual function: vaginal 
dryness
209 142 1 352 (16) 219 124 343 (15) 0.68
Secondary-end-point toxic 
 effects
Clinical skeletal fracture 149 (6.7) 143 (6.4) 0.72
New osteoporosis 37 (1.7) 30 (1.3) 0.39
Cardiovascular events 106 (4.7) 111 (4.9) 0.78
Other solid tumors or he-
matologic malignant 
lesions
43 (1.9) 38 (1.7) 0.58
* The grades of severity are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE),  version 3.0, as follows: 
0 indicates none, 1 mild (intervention not needed), 2 moderate (requiring minimal or noninvasive intervention and limiting age-appropriate 
activities of daily living), 3 severe (medically significant, requiring hospitalization, and limiting self-care activities of daily living), 4 life-threatening, 
and 5 death (related to the adverse event).
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menopausal women, no serious adverse events or 
end-organ toxic effects, including fractures, were 
attributable to exemestane. Mild loss of bone min-
eral density with the aromatase inhibitors is well 
documented, but the annual excess incidence of 
fractures in trials comparing aromatase inhibitors 
and tamoxifen are probably due mainly to the bone-
protective effects of tamoxifen.41,42 After the cessa-
tion of therapy in several large trials comparing 
aromatase inhibitors and tamoxifen in early breast 
cancer, bone mineral density improved and the 
difference in fracture rates was reduced.43-45 In 
these trials, adverse events also attenuated rap-
idly after cessation of treatment and correlated 
with recovery of estrogen levels to their normal 
postmenopausal range. The absence of excess 
clinical fractures in patients treated with exemes-
tane in this study is reassuring. This occurred 
despite similar baseline bone mineral density in 
the two groups and the use of bisphosphonate 
therapy both before and during the study. Al-
though differences in the occurrence of colorec-
tal, lung, and endometrial cancers and malig-
nant melanomas have been reported in tamoxifen 
comparator trials, no differences were seen in this 
trial or in the placebo-controlled MA.17 trial.26,46 
Small numerical, but not significant, differences 
in the number of cardiovascular events have also 
been reported in trials comparing aromatase in-
hibitors with tamoxifen,22,23,46 with more events 
among the patients treated with aromatase in-
hibitors, and these differences may have been due 
to the slightly protective effect of tamoxifen, as sug-
gested by Mouridsen et al.47 It is reassuring that 
when the aromatase inhibitors were compared 
with placebo, these differences were not seen 
either in this prevention trial or in our early 
breast cancer MA.17 trial.
This trial has some limitations. The median 
follow-up of 3 years is relatively short, and al-
though consistent with our projections, the total 
number of breast events (66) was small. The 
optimal duration of endocrine therapy for breast-
cancer prevention is not known, but in a previ-
ous placebo-controlled trial of early breast can-
cer, we found that prolonged aromatase-inhibitor 
therapy was associated with continued reductions 
in the incidence of contralateral breast cancers 
even after the aromatase inhibitor was discon-
tinued.48 The number of women needed to treat 
in MAP.3 to prevent one case of breast cancer is 
94 with 3 years of exemestane therapy, but is 
projected to be 26 at 5 years, although the num-
ber of women who received treatment for a full 
5 years was low. By identifying subgroups of par-
ticipants in the MAP.3 trial who would benefit 
most or who would be most vulnerable to toxic 
effects, one might be able to reduce the number 
needed to treat.
Despite these limitations we found a favor-
able risk-to-benefit ratio with a strong preventive 
effect of exemestane and, with a limited median 
follow-up of 3 years, an excellent safety profile 
across a spectrum of women at average to high 
risk for breast cancer. We reached our protocol-
specified number of events for this final analysis; 
after unblinding, women taking the active drug 
will be offered exemestane to complete 5 years of 
therapy, and MAP.3 sites will have the option of 
offering 5 years of exemestane treatment to those 
initially assigned to placebo. We and others are 
conducting placebo-controlled trials in healthy 
women and patients with early breast cancer to 
evaluate prolonged aromatase-inhibitor therapy in 
postmenopausal women of similar age. The re-
sults of these ongoing trials should contribute to 
our understanding of the long-term efficacy and 
toxicity of aromatase inhibitors.
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